AXL and non-small cell lung carcinoma: Similar bypass activation phenomena have been observed in acquired erlotinib resistance in non-small cell lung cancer (NSCLC), where AXL, an RTK subfamily member, increased and activated Akt/MAPK downstream signaling, leading to a loss of erlotinib’s effectiveness in blocking the Akt/MAPK pathway (34).